A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

NCT02159651 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2024-10-22

No results posted yet for this study

Summary

This study is to evaluate the safety and the efficacy of Prograf in patients with interstitial pneumonia associated with polymyositis / dermatomyositis in acute clinical setting.

Conditions

  • Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Interventions

DRUG

tacrolimus

oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-01
Primary Completion
2019-12-23
Completion
2019-12-23

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159651 on ClinicalTrials.gov